In prostate cancer cells, treatment with epigenetic drugs enhances histone H3 lysine 4 trimethylation (H3K4me3), decreases histone H3 lysine 27 trimethylation (H3K27me3), and induces CLU1 and CLU2 transcription. The gene discussed is CLU; the disease is prostate carcinoma.